Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Wendy Dixon Biography and Net Worth

Director of Alkermes

Dr. Dixon served as Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb from 2001 to 2009. From 1996 to 2001 she was Senior Vice President, Marketing at Merck & Co. and prior to that she held executive management positions at West Pharmaceuticals, Osteotech and Centocor, as well as various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. In addition, Dr. Dixon was a Senior Advisor to The Monitor Group, now Deloitte, from 2010 to 2012. She is currently on the Boards of Directors of Incyte Corporation, bluebird bio, Inc. and Arvinas, Inc. Previously, Dr. Dixon served on the Boards of Directors of Dentsply International, Furiex Pharmaceuticals, Orexigen Therapeutics, Sesen Bio, Inc. (formerly Eleven Biotherapeutics, Inc.), Ardea Biosciences, Inc. and Voyager Therapeutics, Inc.

What is Wendy L. Dixon's net worth?: The estimated net worth of Wendy L. Dixon is at least $1.96 million as of June 10th, 2021. Dr. Dixon owns 66,300 shares of Alkermes stock worth more than $1,955,850 as of December 23rd. This net worth estimate does not reflect any other investments that Dr. Dixon may own. Learn More about Wendy L. Dixon's net worth.
How do I contact Wendy L. Dixon?: The corporate mailing address for Dr. Dixon and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at [email protected]. Learn More on Wendy L. Dixon's contact information.
Has Wendy L. Dixon been buying or selling shares of Alkermes?: Wendy L. Dixon has not been actively trading shares of Alkermes during the last quarter. Most recently, Wendy L. Dixon sold 25,000 shares of the business's stock in a transaction on Thursday, June 10th. The shares were sold at an average price of $25.00, for a transaction totalling $625,000.00. Following the completion of the sale, the director now directly owns 66,300 shares of the company's stock, valued at $1,657,500. Learn More on Wendy L. Dixon's trading history.
Who are Alkermes' active insiders?: Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (Chairman & CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.
Are insiders buying or selling shares of Alkermes?: During the last year, insiders at the sold shares 7 times. They sold a total of 158,155 shares worth more than $4,865,621.63. The most recent insider tranaction occured on December, 9th when EVP Craig C Hopkinson sold 61,151 shares worth more than $1,961,112.57. Insiders at Alkermes own 4.9% of the company. Learn More about insider trades at Alkermes.
Information on this page was last updated on 12/9/2024.

Wendy L. Dixon Insider Trading History at Alkermes

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/10/2021	Sell	25,000	$25.00	$625,000.00	66,300
4/19/2021	Sell	25,000	$20.00	$500,000.00	61,600

Wendy L. Dixon Buying and Selling Activity at Alkermes

Alkermes Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Today's Range

Now: $29.50

$29.18

$29.84

50 Day Range

MA: $28.81

$25.70

$31.46

2 Week Range

Now: $29.50

$22.90

$32.88

Volume

1,337,372 shs

Average Volume

1,820,549 shs

Market Capitalization

$4.77 billion

P/E Ratio

15.13

Dividend Yield

N/A

Beta

0.49

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now